KPTI (Karyopharm Therapeutics) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KPTI Karyopharm Therapeutics Inc KPTI
49 GF Score
Price $1.91
GF Value $5.80
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

KPTI
49GF Score
Karyopharm Therapeutics Inc KPTI
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be undervalued. The current stock price of $1.91 is trading 67.1% below its estimated GF Value™ of $5.80. GuruFocus considers Karyopharm Therapeutics to be Possible Value Trap.

Key valuation signals for KPTI:

  • Interest Expense (Positive):
  • GF Value™: $5.80 vs. price of $1.91 (67.1% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
49GF Score

Get the complete analysis for KPTI

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.91
Price
$5.80
GF Value